Paul Szabolcs
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Paul Szabolcs sits in the upper quartile of US sponsors by registered trial count (#1,806 of 15,742 sponsors by registered trial count).
Paul Szabolcs: 7 sponsored US clinical trials, 7 recruiting.
Paul Szabolcs sponsors 7 registered US clinical trials on ClinicalTrials.gov, 7 of them currently recruiting. 0 of these trials are in Phase 3-4 (later-stage) and 6 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Inflammatory Conditions, with 2 trials.
Upper-quartile sponsor footprint
Paul Szabolcs sits in the upper quartile of the sponsor corpus (#1,806 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.
Open and recent trials
7 total, page 1 of 1
Hematopoietic Stem Cell Transplantation (HSCT) for Common Variable Immunodeficiency (CVID) and Other Autoimmune Manifestations of Primary Immune Regulatory Disorders (PIRD)
NCT07284641
Data Collection Study of Patients With Non-Malignant Disorders Undergoing UCBT, BMT or PBSCT With RIC
NCT04528355
T-Cell Depleted Alternative Donor Bone Marrow Transplant for Sickle Cell Disease (SCD) and Other Anemias
NCT03653338
Autologous Stem Cell Transplantation in Patients With Systemic Sclerosis
NCT03630211
Lung and Bone Marrow Transplantation for Lung and Bone Marrow Failure
NCT03500731
Reduced Intensity Conditioning for Non-Malignant Disorders Undergoing UCBT, BMT or PBSCT
NCT01962415
Autologous Stem Cell Transplantation for Crohn's Disease
NCT00692939
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 3 |
| Phase 2 | 3 |
Therapeutic Areas
What is open in the Paul Szabolcs pipeline
7 recruiting of 7 indexed (100% open).
Phase mix: 0 late (III/IV) vs 6 early (I/II) (early-phase heavy).
Top condition: Inflammatory Conditions (2 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Paul Szabolcs: open-pipeline peers nationwide
Peers matched on 7 registered trials and 100% open enrollment, not the therapeutic-area sidebar.
Paul Szabolcs sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 7 trials (± recruiting share)
- 3M · 7 trials · 0% recruiting
- 4Life Research · 7 trials · 0% recruiting
- 89bio · 7 trials · 29% recruiting
- Abbott Diagnostics Division · 7 trials · 0% recruiting
Sponsors near 100% open enrollment (± trial volume)
- AAVantgarde Bio Srl · 100% recruiting · 2 trials
- Acorn Biolabs · 100% recruiting · 3 trials
- Acrivon Therapeutics · 100% recruiting · 2 trials
- ADARx Pharmaceuticals · 100% recruiting · 4 trials
Related
What to do with this Paul Szabolcs page
7 registered trials is a research-attention snapshot, not an endorsement of Paul Szabolcs or any single study.
- 7 of Paul Szabolcs's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Inflammatory Conditions is the condition Paul Szabolcs studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Inflammatory Conditions trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Paul Szabolcs pipeline card: 7 registered trials from official public datasets.Report a data error.